Semax
Neuropeptides
£30.00per vial
Semax is a synthetic heptapeptide analogue of the ACTH(4-10) fragment, catalogued for neuropeptide and neurotrophic signalling research. The sequence MEHFPGP carries a C-terminal Pro-Gly-Pro extension that resists peptidase cleavage, which is the modification that makes the fragment stable enough for controlled experimental work.
For laboratory research only. Not for human consumption. No medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
This vial is sealed for the protection of health and hygiene. Under regulation 28(1)(e) of the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013, the 14-day right to cancel is lost for this item once that seal is broken. While the seal is intact the right applies in full.
Semax cannot be listed to research users in Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. Verify local eligibility before ordering.
Listed
- Molecular weight
- 813.9 g/mol
- Sequence
- MEHFPGP
- Presentation
- Pre-mixed liquid, 3ml vial
For laboratory research only. Not for human consumption. No medical claims.
- UK DISPATCH
- TRACKED SHIPPING
- COA PER BATCH
- SECURE PAYMENT
§01Compound Profile
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
HPLC
Purity by chromatography
ANALYSED
MASS SPECTROMETRY
Identity confirmation
ANALYSED
PUBLIC COA
Every batch number resolves to its Certificate of Analysis
DOCUMENTED
§02The Science
Published constants and presentation for Semax, as catalogued.
Every figure in this list is a published constant or a presentation fact. None of it is an analytical result: the measured figures live on the Certificate of Analysis for the batch.
- Molecular weight
- 813.9 g/mol
- Sequence
- MEHFPGP
- Presentation
- Pre-mixed liquid, 3ml vial
- Batch reference
- SX5609
Molecular weight source: PubChem CID 9811102.
§03Certificate of Analysis
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
| PARAMETER | METHOD | RESULT |
|---|---|---|
| Purity | HPLC | 98.4% |
| Identity | Mass spectrometry | Confirmed |
SX5609 · 2026-07-02
§04Compound details
Semax derives from adrenocorticotropic hormone, specifically the 4-10 fragment, which is the region of the parent hormone associated with central nervous system activity rather than steroidogenic activity. Attaching Pro-Gly-Pro at the C-terminus slows enzymatic degradation substantially. The result is a heptapeptide, MEHFPGP, that remains measurable long enough to characterise in a laboratory setting while retaining the fragment's signalling profile.
The pathway that dominates the published literature is neurotrophic factor expression. Preclinical studies examine the compound's influence on brain-derived neurotrophic factor and nerve growth factor transcription in hippocampal and cortical tissue, along with the downstream tropomyosin receptor kinase signalling those factors drive. Because the effect is transcriptional rather than direct receptor agonism, the experimental methods are typically expression assays and time-course work rather than binding studies.
Secondary research contexts include monoaminergic modulation, where the compound features in studies of dopaminergic and serotonergic turnover, and hypoxia and ischaemia models, where it appears in work on antioxidant enzyme expression and cerebral perfusion in animal subjects. Much of the foundational literature is Russian-language and predates Western replication, which is itself a stated reason the compound continues to attract independent laboratory investigation. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Semax is listed as a pre-mixed liquid in a sealed 3ml vial, at 10mg and 30mg. There is no reconstitution step for the research user to perform, and no lyophilised powder to handle.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry, which for a short peptide like this one is what separates the target sequence from truncated synthesis products of similar retention time. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number that resolves to the public Certificate of Analysis for its batch. The 10mg and 30mg listings are analysed as separate lots and carry separate Certificates of Analysis, each reporting the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it.
Research Use Only
Semax is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about Semax. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for Semax relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
Semax cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
Research Context
Semax derives from adrenocorticotropic hormone, specifically the 4-10 fragment, which is the region of the parent hormone associated with central nervous system activity rather than steroidogenic activity. Attaching Pro-Gly-Pro at the C-terminus slows enzymatic degradation substantially. The result is a heptapeptide, MEHFPGP, that remains measurable long enough to characterise in a laboratory setting while retaining the fragment's signalling profile.
The pathway that dominates the published literature is neurotrophic factor expression. Preclinical studies examine the compound's influence on brain-derived neurotrophic factor and nerve growth factor transcription in hippocampal and cortical tissue, along with the downstream tropomyosin receptor kinase signalling those factors drive. Because the effect is transcriptional rather than direct receptor agonism, the experimental methods are typically expression assays and time-course work rather than binding studies.
Secondary research contexts include monoaminergic modulation, where the compound features in studies of dopaminergic and serotonergic turnover, and hypoxia and ischaemia models, where it appears in work on antioxidant enzyme expression and cerebral perfusion in animal subjects. Much of the foundational literature is Russian-language and predates Western replication, which is itself a stated reason the compound continues to attract independent laboratory investigation. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Analysis and Documentation
Semax is listed as a pre-mixed liquid in a sealed 3ml vial, at 10mg and 30mg. There is no reconstitution step for the research user to perform, and no lyophilised powder to handle.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry, which for a short peptide like this one is what separates the target sequence from truncated synthesis products of similar retention time. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a batch number that resolves to the public Certificate of Analysis for its batch. The 10mg and 30mg listings are analysed as separate lots and carry separate Certificates of Analysis, each reporting the lot reference, the HPLC result, the mass-spectrometry result, the analysis date, and the laboratory that ran it.
Compliance Notice
Research Use Only
Semax is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about Semax. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for Semax relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
Semax cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
§05Related compounds
§06Questions
No. Semax is catalogued strictly for in-vitro laboratory research. It is not for human or veterinary consumption and no medical claims are made.
Neurotrophic factor expression, principally BDNF and NGF transcription in hippocampal and cortical tissue, alongside monoaminergic modulation and hypoxia models.
The ACTH(4-10) fragment, extended at the C-terminus with Pro-Gly-Pro to resist peptidase cleavage. The full sequence is MEHFPGP.
Pre-mixed liquid in a sealed 3ml vial, at 10mg and 30mg. No reconstitution is required.
HPLC for purity and mass spectrometry for identity, on every batch, before it is listed. No further assay is claimed.
Every batch has a document.
The Certificate of Analysis for a batch is published when that batch is released. Your batch number resolves to the report.
For laboratory research only. Not for human consumption. No medical claims.
